What We're Reading: Page 182
Industry reads hand-picked by our editors
Jul 15, 2020
-
Harvard Business School Working Knowledge
Merck CEO Ken Frazier Discusses a COVID Cure, Racism, and Why Leaders Need to Walk the Talk
-
Bloomberg
Covid Vaccine Front-Runner Is Months Ahead of Her Competition
-
The Wall Street Journal
Biotech Properties Draw Billions of Dollars as Other Real Estate Languishes
Jul 14, 2020
Jul 13, 2020
Jul 10, 2020
-
Forbes
This Startup Might Finally Cure Sickle Cell Disease—After A Century Of Racist Neglect
-
Regulatory Focus
Marks on COVID-19 vaccine efficacy, EUAs and challenge trials
-
The Wall Street Journal
German Biotech Sees Its Coronavirus Vaccine Ready for Approval by December
-
The New York Times
Regeneron Scientists Raced To Find Antibodies To Fight Covid-19. Then The Coronavirus Found Them.
Jul 09, 2020
-
Nature
Scientists make precise edits to mitochondrial DNA for first time
-
The New York Times
U.S. Weighs Early Vaccine Access for Minorities and Others at Risk
-
Axios
An infodemic of misinformation is crippling the coronavirus response
-
Reuters
Bolsonaro bets 'miraculous cure' for COVID-19 can save Brazil - and his life
Jul 08, 2020
-
The New York Times
‘It Will Consume Your Life’: 4 Families Take On Rare Diseases
-
POLITICO
The Dangerous Race for the Covid Vaccine
-
Evaluate Vantage
What pandemic? Biotech floats break records
-
BioCentury
FDA credibility on the line with White House pressure on hydroxychloroquine
Jul 07, 2020
-
The New York Times
The Fullest Look Yet at the Racial Inequity of Coronavirus
-
Reuters
Moderna spars with U.S. scientists over COVID-19 vaccine trials
-
FierceBiotech
Death in Cellectis off-the-shelf CAR-T trial triggers FDA hold
-
STAT
Data show panic, disorganization dominate the study of Covid-19 drugs
Previous
